衰老驱动代谢相关脂肪性肝病的机制及靶向治疗策略研究进展

打开文本图片集

Abstract：Metabolicassociatedfaty liverdisease（MAFLD）isaliverdiseaseasociated withmetabolicdisorders，and itis characterizedbyexcesivefatdepositioninhepatoctesandiscloselyasociatedwithinsulinresistanceandgeneticsuscetibility. Aging isanimportantfactorintheprogressionof MAFLDandispositivelycorrelatedwiththemortalityrateof patients with MAFLD.The pathophysiological mechanismsofMAFLDinvolve lipid metabolismdisorders，nsulinresistance，inflammation，and oxidativestress，andaging exacerbates thepathological processofMAFLDbyfurtheraffecting these keymechanisms.Cell senescence isanimportantfactorinorganismalaging，ndtherapeuticstrategies targetingsenescentcelscanrducetheumberof senescentcelsorinhibittheiflammatoryfactorsseretedbysuchcells，therebyhelping toslowdowntheprogressionofMAFL. Inaddition，thescreeningofnovelregulatoryfactorsprovidesnewtargetsforthedevelopmentofnewdrugsforMAFLDtreatment. Althoughseveralantiagingterapieshaveenteredclinicaltrials，furtherstudiesareneededtovalidatethespecificityandpotetial liverdamageof these therapiesduetothecomplex mechanismsof agingonthe liver.Transforming multisystemmetabolic dysfunction therapies for MAFLD into specialized therapies for aging may provide new ideas for MAFLDdrug development.

Key words：Non-alcoholic Fatt Liver Disease；Celular Senescence；Aging；Lipid Metabolism Disorders；Insulin Resistance Inflammation

非酒精性脂肪性肝病是一种以除外酒精和其他明确的损肝因素所致的以肝细胞内脂肪过度沉积为主要特征的临床病理综合征，近期国际共识将其更名为代谢相关脂肪性肝病（metabolicassociated fatty liver disease，

MAFLD），更关注脂肪肝与代谢之间的双向作用。（剩余18518字）